Healthcare Wire Hong Kong
SEE OTHER BRANDS

Your health and wellness news from Hong Kong

Healthcare Wire Hong Kong: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Hong Kong.

Press releases published on August 22, 2025

KFSHRC 採用阿聯酋捐贈器官進行跨境心臟移植,拯救沙地一名 7 歲兒童性命

KFSHRC 採用阿聯酋捐贈器官進行跨境心臟移植,拯救沙地一名 7 歲兒童性命

利雅德,沙地阿拉伯, Aug. 22, 2025 (GLOBE NEWSWIRE) -- 位於利雅德的King Faisal Specialist Hospital and Research Centre (KFSHRC) 採用由阿聯酋阿布扎比一位腦死亡捐贈者提供的器官,成功為沙地阿拉伯一名 7 歲的兒童進行了心臟移植手術,拯救了該兒童的性命。 這次複雜的手術由 Saudi Center for Organ Transplantation(沙地器官移植中心)與阿聯酋 National Program for …

NMDP Named ‘Best Place to Work’ Fifth Year in a Row

NMDP Named ‘Best Place to Work’ Fifth Year in a Row

MINNEAPOLIS, Aug. 22, 2025 (GLOBE NEWSWIRE) -- NMDPSM, a global nonprofit leader in cell therapy, announced the Minneapolis / St. Paul Business Journal honored the organization for the fifth consecutive year as a top workplace, notching 4th place in the ' …

CrazyBulk Supplements Bulking Stacks 2025: Crazy Bulk Launch “Safest Legal Steroid Alternatives” for Muscle Growth & Strength for Over 50's

CrazyBulk Supplements Bulking Stacks 2025: Crazy Bulk Launch “Safest Legal Steroid Alternatives” for Muscle Growth & Strength for Over 50's

new york, Aug. 22, 2025 (GLOBE NEWSWIRE) --   [New York, 22 AUGUST] — CrazyBulk, a well-known name in performance and fitness nutrition, is revolutionizing the bodybuilding community with its potent range of Bulking Supplements that enable athletes and …

Positron Corporation Announces New Corporate Headquarters and Strategic Redomiciling to Delaware

Positron Corporation Announces New Corporate Headquarters and Strategic Redomiciling to Delaware

North Tonawanda, NY, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced that the Company had established a new corporate headquarters in …

Global Liquid Biopsy Market Set to Reach USD 7.05 Billion by 2030 | MarketsandMarkets™

Global Liquid Biopsy Market Set to Reach USD 7.05 Billion by 2030 | MarketsandMarkets™

Delray Beach, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The global liquid biopsy market, valued at US$3.65 billion in 2024, stood at US$4.03 billion in 2025 and is projected to advance at a resilient CAGR of 11.8% from 2025 to 2030, culminating in a forecasted …

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

New Taipei City, Taiwan, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated …

Beta-Glucan Market Set to Reach USD 800 Million by 2029, Driven by Expanding Applications Across Industries

Beta-Glucan Market Set to Reach USD 800 Million by 2029, Driven by Expanding Applications Across Industries

Delray Beach, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- According to MarketsandMarkets™, The report beta-glucan market size is projected to grow from $542 million in 2024 to $800 million by 2029, at a CAGR of 8.1%. This growth is being driven by the rising …

Global Surgical Sutures Market Poised to Reach USD 6.65 Billion by 2030 | MarketsandMarkets™

Global Surgical Sutures Market Poised to Reach USD 6.65 Billion by 2030 | MarketsandMarkets™

Delray Beach, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The global surgical sutures market, valued at US$4.56 billion in 2024, stood at US$4.84 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a …

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today …

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today …

Repligen Corporation to Present at Upcoming September Conferences

Repligen Corporation to Present at Upcoming September Conferences

WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences. The Wells Fargo …

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today …

CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist

CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist

Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025 CLINUVEL’s primary listing on the ASX will remain unchanged as a result of the ADR uplist preparation of …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions